Robert M.  Davis net worth and biography

Robert Davis Biography and Net Worth

Rob Davis is chief executive officer and president of Merck.

Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories.  Prior to that, he was executive vice president, Global Services, and the company’s chief financial officer.

Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services.  He became president in April 2021 and CEO and a member of the board of directors on July 1, 2021.

Prior to joining Merck, Rob was corporate vice president and president of Baxter’s Medical Products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s Renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.

Rob serves on the board of directors for Duke Energy Corporation and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a board member of Project Hope, a non-profit organization focused on empowering health care workers to deliver expert care when and where it is needed most. 

Rob received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.

What is Robert M. Davis' net worth?

The estimated net worth of Robert M. Davis is at least $23.94 million as of April 28th, 2023. Mr. Davis owns 271,817 shares of Merck & Co., Inc. stock worth more than $23,935,661 as of March 26th. This net worth approximation does not reflect any other investments that Mr. Davis may own. Additionally, Mr. Davis receives an annual salary of $5,570,000.00 as CFO at Merck & Co., Inc.. Learn More about Robert M. Davis' net worth.

How old is Robert M. Davis?

Mr. Davis is currently 57 years old. There are 7 older executives and no younger executives at Merck & Co., Inc.. Learn More on Robert M. Davis' age.

What is Robert M. Davis' salary?

As the CFO of Merck & Co., Inc., Mr. Davis earns $5,570,000.00 per year. Learn More on Robert M. Davis' salary.

How do I contact Robert M. Davis?

The corporate mailing address for Mr. Davis and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at investor_relations@merck.com. Learn More on Robert M. Davis' contact information.

Has Robert M. Davis been buying or selling shares of Merck & Co., Inc.?

Robert M. Davis has not been actively trading shares of Merck & Co., Inc. during the last quarter. Most recently, Robert M. Davis sold 143,329 shares of the business's stock in a transaction on Friday, April 28th. The shares were sold at an average price of $114.93, for a transaction totalling $16,472,801.97. Following the completion of the sale, the chief executive officer now directly owns 271,817 shares of the company's stock, valued at $31,239,927.81. Learn More on Robert M. Davis' trading history.

Who are Merck & Co., Inc.'s active insiders?

Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Cristal Downing (Insider), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Inge Thulin (Director), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.

Are insiders buying or selling shares of Merck & Co., Inc.?

During the last year, Merck & Co., Inc. insiders bought shares 1 times. They purchased a total of 2,833 shares worth more than $250,012.25. During the last year, insiders at the sold shares 1 times. They sold a total of 2,361 shares worth more than $209,562.36. The most recent insider tranaction occured on February, 6th when Director Inge G Thulin bought 2,833 shares worth more than $250,012.25. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..

Information on this page was last updated on 2/6/2025.

Robert M. Davis Insider Trading History at Merck & Co., Inc.

See Full Table

Robert M. Davis Buying and Selling Activity at Merck & Co., Inc.

This chart shows Robert M Davis's buying and selling at Merck & Co., Inc. by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Merck & Co., Inc. Company Overview

Merck & Co., Inc. logo
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Read More

Today's Range

Now: $88.06
Low: $87.31
High: $89.32

50 Day Range

MA: $92.35
Low: $83.01
High: $100.72

2 Week Range

Now: $88.06
Low: $81.04
High: $134.63

Volume

13,807,591 shs

Average Volume

10,310,121 shs

Market Capitalization

$222.44 billion

P/E Ratio

13.08

Dividend Yield

3.42%

Beta

0.35